Global Mycosis Fungoides Market Is Expected To Expand At A CAGR Of 4.9% From 2019 To 2027

The latest market report published by Credence Research, Inc. “Global mycosis fungoides Market – Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global mycosis fungoides market is expected to expand at a CAGR of 4.9% from 2019 to 2027.

Market Insights

Mycosis fungoides is most frequently encountered in primary cutaneous lymphoma. The disease progression is slow and indolent with a challenging diagnosis in the early stage of the disease which requires accurate clinical-histopathological correlation. It is a rare disease occurs usually in adults above 50 years of age, the ratio of its occurrence in men to women is 2:1.

As per the research citing brought forward by National Institute of Health (NIH), the global prevalence rate of mycosis fungoides in 1 per 100,000 to 350,000 individuals. It is seen in approximately 70% of the patients suffering with cutaneous T cell lymphoma. There is no permanent cure for the disease. The treatment regimen is decided by the oncologist as per the manifestation of the clinical symptoms during the course of the disease. Either individual or combinatorial therapy is considered for the treatment. In stage 1 a combination of topical treatment of steroids, mechlorethamine gel and localized radiation therapy is recommended by physicians worldwide. In stage 2 HDAC inhibitors and extracorporeal photopheresis is approved for the treatment of mycosis fungoides. In the late stage of the disease monoclonal antibodies are given by systemic circulation to curb the spread of the disease to internal organs. Recently USFDA approved Poteligeo (mogamulizumab) which will further increase the demand for monoclonal antibodies as the first line therapy for the treatment of mycosis fungoides.

In the regional segment North America is spearheading the market representing a share of 31.8%. The major contributing factors favoring its excellent market growth are rising incidence of mycosis fungoides and stringent treatment guidelines stipulated by USFDA. The domicile of key players such as Astellas Pharma, Sanofi S.A., Soligenix, Inc., Yaupon Therapeutics etc. further boost the market growth in North America region. With a market share of 28.4% Europe is placed in the second position owing to the strategic collaboration between academic research institutes and biopharmaceutical giants in developing novel drugs for the treatment of mycosis fungoides. Affordable reimbursement scenario further bolsters the market growth in Europe. Asia Pacific is currently holding 16.2% in the and will be the fastest growing market on account of supportive regulatory environment provided by local healthcare agencies and proactive initiative taken by government for treatment of orphan and rare diseases.

Biopharmaceutical giants spearheading the mycosis fungoides market are Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Sanofi SA, Soligenix, Inc., Varian Medical Systems and Yaupon Therapeutics.

Key Market Movements:

  • Rising incidence of mycosis fungoides in patients above 50 years of age
  • Affordable reimbursement scenario for medicines used in the treatment of mycosis fungoides in developed regions
  • Significant rise in the demand for monoclonal antibodies as the first line therapy agent with promising pipeline during the forecast period

Browse the full report Mycosis Fungoides Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at

The Global mycosis fungoides Market is Segmented into:

Research Period 2017-2027
Base Year2018
Forecast Period 2019-2027
Historical Year 2017
Unit USD Million
Segmentation By Treatment (2017–2027; US$ Mn)
 By Geography Segment (2017–2027; US$ Mn)

*Complete segmentation list is on report page